Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) ...
-
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) ...
-
Caisse Régionale de Crédit Agricole Mutuel Brie Picardie Société coopérative à capital variable, agréée en tant qu’établissement de crédit Siège social : 500 rue Saint-Fuscien 80095 AMIENS...
-
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY...
-
COURTOIS S.A. Toulouse, le 5 août 2025 DECOMPOSITION DES DROITS DE VOTE AU 31/07/2025 Emetteur : Courtois Code Emetteur : ...
-
LEHI, Utah, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today...
-
COMPANY ANNOUNCEMENT No. 227/2025 Tvis, 5 August 2025 Major shareholder announcementWith reference to section 30 of the Danish Capital Markets Act, TCM Group A/S (the "Company") hereby announces...
-
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) today released its financial and operational results and related...
-
Communiqué de presseNicox annonce l’initiation par son partenaire Kowa d’un essai clinique de Phase 3 pour NCX 470 au Japon Kowa, le partenaire exclusif de Nicox au Japon, a initié un essai clinique...
-
Press Release Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of...